- Medical evidence demonstrated in a recent symposium, to be released this September

- Effective in dyslipidemia treatment, such as high blood pressure with high bio absorbable rate



A medical symposium reported that ‘Lipilfen’ (component name: Fenofibrate), a brand-new medicine for dyslipidemia patients that Daewoong Pharmaceutical (President Lee Jong Wook) will release in the 2nd half of the year, has an excellent level of effectiveness. Dyslipidemia is a condition in which the patient has an abnormal amount of lipids such as cholesterol or fat in the blood, which can lead to cardiovascular diseases such as high blood pressure or stroke. 

A spokesperson for Daewoong Pharmaceutical said on the 21st that “new opinions and up-to-date information on the use of Lipilfen and the importance of neutral fats for dyslipidemia was shared in a medical symposium in Seoul chaired by Professor Kim Hyo Soo of SNU Medical School. Professor Kim Sang Hyun (SNU), Professor Han Ki Hoon (Ulsan Univ.), Professor Kim Byeong Ok (Inje Univ.), Professor Park Byeong Eun (Dankook), and Professor Jo Sang Ho (Hanrim) attended the symposium, which was held under the title of ‘Triglyceridemia and reconsideration of Fibrate.”

Last May, Daewoong Pharmaceutical obtained its domestic sales right from Ethypharm in France and is scheduled to release Lipilfen in September. The product has proved effective in increasing HDL-C and decreasing neutral fats and LDL-C with its fenofibrate medicine, which improves bio absorbable rate using micronized technology.  

 Professor Kim Sang Hyeon remarked, “Controlling neutral fat and HDL-C is as important as controlling LDL-C in the treatment of dyslipidemia. In particular, high value neutral fat may cause atheroscelerosis by affecting HDL-C or LDL-C. Thus, fenofibrate is helpful for comprehensively controlling risk factors.” Professor Han Ki Hoon also said “it is good to use Lipilfen with Statin medicine for the high risk group having high neutral fat and low HDL-C. According to a recent clinical report of ACCORD (Action to Control Cardiovascular Risk in Diabetes) on Lipid published in the ASS in the US, fenofibrate has shown a better improvement of neutral fat and HDL-C when it was used with Statin medicine rather than in a single treatment. In particular, combined treatment can be considered for patients whose dyslipidemia cannot be controlled by Statin with neutral fat increase and HDL-C decrease.”
 In his presentation titled “Benefit and expectation of combined treatment of statin and fenofibrate,” Professor Kim Byeong Ok argued that “combined treatment of fibrate and statin has proven effective for patients who have high neutral fats and low HDL-C.”

Meanwhile, Lipilfen is one of the most widely used fenofibrate medicines in Europe. The domestic market for fenofibrate medicines has a size of about KRW 23 billion as of 2010.